PPARG and breast cancer: While at this stage, we cannot provide a direct effect of PPAR-γ agonist treatment on the abundance of LIPECs in BC patients, nor a causal role of LIPECs in BC clinical outcome, our findings nevertheless warrant further investigation into the LIPEC phenotype and its role in BC progression and survival.